Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Open-label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) as First-line Therapy in Participants With Advanced Merkel Cell Carcinoma (KEYNOTE-913))

Trial Profile

A Phase 3 Open-label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) as First-line Therapy in Participants With Advanced Merkel Cell Carcinoma (KEYNOTE-913))

Recruiting
Phase of Trial: Phase III

Latest Information Update: 16 Feb 2019

At a glance

  • Drugs Pembrolizumab (Primary)
  • Indications Carcinoma; Merkel cell carcinoma
  • Focus Registrational; Therapeutic Use
  • Acronyms KEYNOTE-913
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 30 Jan 2019 Status has been changed from Not yet recruiting to Recruiting.
    • 20 Nov 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top